Background. Negative symptoms (NS) are a central part of the symptomatology of schizophrenia, which is highly correlated to the functional outcome. Disturbances of the brain reward system are suggested to be central in the pathogenesis of NS by decreasing motivation and hedonic experiences. In this study, we compared reward-related brain activity in patients improving and not improving in NS after treatment with amisulpride. Methods. Thirty-nine antipsychotic-naive patients and 49 healthy controls completed functional magnetic resonance imaging with a modified monetary incentive delay task. Psychopathology of the patients was characterised with Positive and Negative Syndrome Scale (PANSS), and they were treated with individual doses of amisulpride (mean 271 mg) for 6 weeks, after which the examinations were repeated. Results. Patients improved on positive, general, and total PANSS score after treatment (P < .001). Fourteen patients had ≥20% improvement of NS, whereas 25 patients improved <20%. At baseline, one-way analysis of variance showed group difference bilaterally in the caudate nucleus and in the right nucleus accumbens (all P < .002), which was caused by decreased reward anticipation activity in the nonimproving patients compared to healthy controls. There was a significant group × time interaction, with the healthy controls and the improvers decreasing and the nonimprovers increasing in reward anticipation activity after treatment, most pronounced in the left caudate nucleus (P = .001). Discussion. Patients improving in NS score had a less aberrant reward system at baseline, but reward related activity was reduced over time. Patients not improving in NS showed decreased striatal reward-activity at baseline, which improved over time. Whether this is associated with alteration in working memory and reward learning or with pronounced symptoms within specific domains of NS may be addressed in future studies.
Background
Negative symptoms (NS) are a central part of the symptomatology of schizophrenia, and they are highly correlated to the functional outcome.
1,2 NS can be divided into primary and secondary 3 ; primary NS are thought to be a central element of the pathophysiology and are suggested to have a specific underlying neurobiological correlate, 3 whereas secondary NS are secondary to medical treatment or to other symptoms, like anxiety, depression, or psychoses. Several neurobiological changes may serve as the basis for developing NS, among these are disturbances of the brain reward system. 4 The neural circuits of the brain reward system are essential for signaling motivation and pleasure. [5] [6] [7] [8] Reward disturbances have consistently been found in antipsychotic-naive patients as well as medicated patients with a diagnosis of schizophrenia. [9] [10] [11] [12] Several studies using functional magnetic resonance imaging (fMRI) have found attenuated signal in relation to salient cues. 9, 13, 14 In some studies, a reduced signal has been linked to the level of NS, 9, [15] [16] [17] whereas other studies have found a relation to the level of positive symptoms. 13, 14 Likewise, a number of studies have found an association between a high level of NS and attenuated activity in frontal brain regions during outcome evaluation. [17] [18] [19] Furthermore, aberrant prediction error coding has been linked to NS in schizophrenia patients. Although these findings may indicate an association between reward disturbances and NS, there are a number of studies, which have not been able to replicate these findings. 10, 13, 23 Additionally, almost all the mentioned studies have been cross sectional studies in medicated patients. This is a potential confounding factor, as several studies indicate that antipsychotic medication have a direct effect on the activity in the brain reward system. 15, 24, 25 There are, so far, no longitudinal studies examining to what extent antipsychotic associated changes in the brain reward system may relate to changes in NS.
Most antipsychotic drugs do not have much direct treatment effect on NS, 26 and first-generation antipsychotics may even worsen NS. 27 However, low doses of amisulpride have been suggested to improve NS by presynaptic dopamine D2 blockade, and a clinical effect on NS has been found in metaanalyses. 28, 29 Recently, Levine and Leucht 30 showed that this effect on NS may only be seen in some patients. They identified different response trajectories, where 45% of the patients had a rapid or a moderate improvement in their NS during a period of 12 weeks whereas the rest of the patients did not improve. 30 In antipsychotic-naive patients with schizophrenia, we have previously found a correlation between positive symptoms and attenuated response in striatum during reward anticipation whereas we did not find any correlation with NS. 13 These patients were a part of a large cohort of first-episode patients who were examined before and after amisulpride monotherapy. Inspired by the different response trajectories, we investigated here whether patients improving and not improving in NS during treatment differed in the underlying reward disturbances. Furthermore, we investigated whether different medication effects on reward anticipation could explain the different response trajectories for patients improving and not improving in NS during medical treatment. We expect the attenuated response to normalize in the patients improving in NS, whereas it will be unchanged or even worsened in the patients not improving. Furthermore, we expect that this medication effect will induce a correlation between NS and reward anticipation activity in the medicated patients.
Methods

Methods and Materials
The study was approved by the Danish National Committee on Biomedical Research Ethics (H-D-2008-088) and it was conducted in accordance with the Declaration of Helsinki II. All participants signed informed consent and the study was registered in clinicaltrials.gov, identifier: NCT01154829.
Participants
As a part of a large multimodal study 69 antipsychotic-naive first episode schizophrenia patients aged 18 to 45 years were recruited from psychiatric hospitals and outpatient centers in the Capital Region of Denmark. All patients had never received antipsychotic medication or ritalin. Patients had to fulfil the ICD-10 (International Statistical Classification of Diseases and Related Health Problems, 10th Revision) diagnostic criteria of schizophrenia or schizoaffective psychoses, the diagnose was based on a structured diagnostic interview (Schedule of Clinical Assessment in Neuropsychiatry [SCAN], version 2.1). 31 Previous diagnoses of drug dependency according to ICD-10 or current occasional use of drugs were accepted, but patients with a current diagnosis of drug dependency were excluded. Likewise, we excluded patients treated with antidepressants within the last month or during the study period. Patients were allowed to receive benzodiazepines or sleep medication, but not later than 12 hours prior to scans. Current drug status was measured by urine test (Rapid Response, Jepsen HealthCare). Furthermore, patients were required to have a normal physical and neurological examination and no history of major head injury.
After baseline examination, patients were treated for 6 weeks with individual doses of amisulpride. To avoid use of anticholinergic medication, doses were individually adjusted according to the clinical impression of symptoms and adverse effects, particularly sedation and extrapyramidal symptoms.
Psychopathology of the patients was measured with the Positive and Negative Syndrome Scale (PANSS) 32 and level of function was estimated using Global Assessment of Function (GAF). 33 A group of healthy controls matched on age, gender, and parental socioeconomic status, who did not receive medication was examined at baseline and follow-up.
Subjects included in the analyses presented here do partially overlap with those presented in previous publications of the cohort on fMRI 13, 25, 34 as well as other modalities.
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Experimental Design and Task
To elicit striatal activation in response to cues indicating monetary gain and loss, we used a modified variant of the monetary incentive delay (MID) task described by Knutson et al 40 and modified by Cooper and Knutson. 41 Details on the paradigm is described elsewhere, 13, 25 but in short, patients were initially presented with a cue indicating one of six trial conditions. After a short delay, a visual target briefly appeared on the screen, and patients were instructed to press a button while target was on screen. Target time was individually adjusted to reach a hit rate of around 66%. After another delay, feedback on the monetary outcome was shown. Each trial lasted 15 seconds and 1 run consisted of 72 trials. Participants practiced the task for 10 minutes before going to the scanner, both at baseline and follow-up.
Imaging
Functional and structural MRIs were performed with a Philips Achieva 3.0T whole body MRI scanner (Philips Healthcare, Best, Netherlands) using an 8-channel SENSE Head coil (Invivo, Orlando, USA). In each scanning session whole-brain 3-dimensional (3D) high-resolution T1-weighted structural images were acquired for anatomical reference (repetition time 
Data Analysis
fMRI analyses were conducted using tools from the FMRIB Software Library (FSL, John Radcliffe Hospital, Oxford, UK; https://fsl.fmrib.ox.ac.uk/fsl/fslwiki/). Images were corrected for slice-timing and 3D motion effects. Spatial smoothing was performed with a 5-mm full-width at half-maximum Gaussian kernel, and low-frequency noise was reduced using a high-pass filter of 200 seconds. The functional images were co-registered to the 3D anatomical images and both were transformed into MNI space (Montreal Neurological Institute, Quebec, Canada).
For the first level analyses, the general linear model presented in Nielsen et al 13 was used. It consists of a total of 15 predictors, each describing different elements of the task, and all explanatory variables were convolved with the hemodynamic response function. Individual anticipation contrast images were computed to estimate the salience effect. This was modeled by uncertain gain and loss cues (anticipation of events where outcomes were performance dependent) versus neutral cues (anticipation of events where outcome was zero regardless performance). This contrast was chosen as it has previously showed the highest contrast signal in healthy controls and it was the contrast where the most pronounced alterations was found in patients. 13 
Regions of Interest
Previous studies have reported findings from ventral striatal regions, and we therefore focused our analyses on these regions. We defined 4 regions of interest (ROIs): the nucleus accumbens and head of nucleus caudatus, both bilaterally. We wanted data from the areas where the paradigm showed significant contrast activation during reward anticipation and where a pronounced group difference between the whole group of patients and healthy controls was found. These criteria were met using the definition described in Zink et al 42 and the ROIs were defined as a 6-mm radius spherical region centred in the MNI coordinates ±22, 4, and 4 and ±10, 14, and −6. The mean z-scores of activation contrast from these bilateral regions were extracted and used for further analyses.
For illustrative purpose, group comparisons at baseline and follow-up were carried out voxel-wise within a basal ganglia mask (Harvard subcortical atlas). For explorative purpose, group comparisons at baseline and follow up were carried out voxelwise using a whole brain approach. The resulting z statistic images were thresholded using clusters determined by Z > 2.3 and a corrected cluster significance threshold of P = .05. 43 
Statistics
Demographic and psychopathological differences between patients who completed the study and patients who dropped out were analyzed with independent-samples t test and Pearson's chi-square test.
The 39 patients completing the study were grouped according to their improvement on PANSS NS score, calculated using the method described in Obermeier et al. 44 The traditional threshold of a 20% reduction in PANSS NS scores was used. 45, 46 Differences in demography and psychopathology between patients improving and those not improving were analyzed using the independent-samples t test and a possible group × time interaction for change in psychopathology was analyzed with repeated-measures analysis of variance (ANOVA).
For the behavioral measures and the imaging data, the healthy controls were included as a third group in the analyses.
Total monetary gain was compared with 3 * 2 repeatedmeasures ANOVA, with group as between factor and time as within factor. Hit rate and reaction time were analyzed with 3 * 2 * 4 repeated-measures ANOVA with group as between factor and time and trial-type as within factors. Only the 4 conditions (the uncertain gain, uncertain loss, and the 2 neutral conditions) used for the fMRI contrasts were included in these analyses.
Group differences in the z scores of the salience contrast extracted from each of the ROIs were examined by one-way ANOVA at baseline, and differences over time was examined using repeated-measures ANOVA. As there was a significant age difference between the 2 groups of patients, the analyses were done with and without age as a covariate.
Correlation between PANSS NS score and extracted salience contrast values for each ROI was analyzed for baseline, followup, and for change using spearman correlation. Likewise, spearman correlation was used to analyse a possible relation between medication doses at follow-up and change in PANSS total, positive, negative, and general scores.
Results
A total of 69 patients were included during the period between December 2008 and 2013, psychopathology was obtained on 63 patients, and baseline fMRI scans were obtained on 58 patients. At follow-up, fMRI scans and/or PANSS scores were not available for 19 patients, which left us with fMRI and psychopathology data on 39 patients (Table 1) . Reasons for not completing the study are listed in Figure 1 . The patients not included in the longitudinal analyses had a small but significantly higher PANSS total, negative and general score at baseline as compared with patients who were also examined at follow up (all P < .05). Likewise, they had a lower GAF score at baseline. Patients included in the further analyses were characterized as described in Table 1 . At follow-up, these patients received an average daily dose of 271 mg amisulpride (SD = 174, range = 50-800 mg). For the whole group of patients, there was no improvement in PANSS NS score, but a significant improvement in the total PANSS score (t = 7.2, P < .001); the PANSS positive score (t = 7.7, P < .001); the PANSS general score (t = 7.8, P < .001); and in GAF score (t = 5.6, P < .001). Please see Table 1 for details.
Subgrouping the patients according to their treatment response, 14 patients were characterized as improvers as they improved more than 20% on NS score. These improvers were significantly older than the nonimprovers (t = 3.3, P = .002), and they had a significantly higher PANSS NS score (t = 3.2, P = .003) and PANSS total score (t = 2.1, P = .04) at baseline. There were no significant differences in other psychopathology measures or in mean amisulpride dose. Comparing the change in psychopathology between the improving and the nonimproving group, there was a significant group × time interaction not only in NS score (F 1, 37 = 57, P < .001) but also in PANSS total score (F 1, 37 = 19.5, P < .001) and PANSS general score (F 1,37 = 6.6, P = .014), where a larger improvement was found in the group of patients improving in NS. Although the GAF score improved numerically more in the nonimproving patients, there was no significant group × time interaction (Table 2) = 3.4, P = .067). Hit rate was highest in the uncertain gain and loss conditions and improved at follow-up for all 3 groups. There were no group differences and no interactions. = 22, P = .014), but no main effect of group. All groups showed a shorter reaction time for uncertain events and improved their reaction times at follow-up. There were no interactions. Thus, all groups increased their effort in the uncertain trials, and all groups improved their hit-rate and reaction times in the uncertain trials over time.
fMRI Analyses of Anticipation Response
Baseline. The average contrast signal of the salience contrast during reward anticipation was extracted from the preselected ROIs. One-way ANOVA of reward anticipation activity showed a significant group difference in nucleus caudatus bilaterally (F 85, 2 = 8.2, P = .001; F 85, 2 = 7.1, P = .001) and right nucleus accumbens (F 85, 2 = 6.5, P = .002), whereas left nucleus accumbens only differed at a trend level (P = .055). Post hoc tests showed that the group effect in bilateral caudate and right nucleus accumbens was caused by a decreased contrast signal in the nonimproving patients compared with the healthy controls. There was no difference between the healthy controls and the patients improving in NS in any of the ROIs. In both of the left ROIs, there was a trend level difference between the 2 patient groups (P = .08); see Figure 2 .
A voxel-wise analysis within the basal ganglia mask similarly showed a significantly lower striatal activity in the nonimproving patients compared to the healthy controls using small volume correction. There were no significant differences between the 2 groups of patients or between the patients improving on NS and the healthy controls. The contrast activation for each of the groups and the significant group difference is illustrated in Figure 3 . = 3.1, P = .05). Both healthy controls and NS improvers had a decrease in contrast signal over time, whereas the nonimprovers showed an increase in reward anticipation activity after treatment (Figure 2) . The same pattern was found bilaterally in nucleus accumbens, although these findings were not significant (P = .074 and P = .059). Introducing age as a covariate altered the results slightly, as group × time interaction in the right nucleus accumbens became significant (F 2, 1, 84 = 3.5, P = .037) whereas left nucleus accumbens was still only showing group difference at a trend level (P = .055). After correcting for age, there was still a significant group time interaction in the left and right caudate (F 2, 1, 84 = 9.1, P < .001 and F 2, 1, 84 = 4.1, P = .02). The voxel-wise analyses within the basal ganglia mask of the follow-up data similarly showed that the nonimproving patients now had a significant contrast response bilaterally, which was also the case for the healthy controls. The group difference found at baseline between the nonimproving patients and the healthy controls could no longer be detected on the left side and was diminished on the right side (Figure 3 ). There was no significant signal in the improving patients at follow-up and no other group differences.
Voxel-wise Group Comparison. For explorative purpose, pairwise group comparisons were performed using a whole brain approach. At baseline, the nonimproving patients had a reduced contrast signal in several areas outside and inside the basal ganglia compared with the healthy controls (Figure 4) . At followup, this difference was no longer present in left striatum or in the frontal areas. On the contrary, the nonimproving patients had an increased contrast signal in the right frontal area at follow-up compared with the improving patients. Likewise, the healthy controls had an increased signal in the frontal areas bilaterally compared with nonimproving at follow-up, which was not present at baseline. There were no areas at baseline or at follow-up where healthy controls had a decreased signal compared with any of the patient groups, and no areas where the nonimproving patients had a decreased signal compared with improving patients.
Correlations. There were no significant correlations between baseline PANSS NS score and the extracted salience contrast signal at baseline for any of the ROIs. Likewise, no correlations were found between follow-up PANSS NS score and salience contrast signal at follow-up. For the left caudate, there was a negative correlation between change in PANSS NS score and change in salience contrast signal (r = −0.38, P = .022), thus the patients with less improvement in NS had the highest increase in the contrast signal. This result, however, did not survive correction for multiple comparison.
Additionally, there was no correlation between medication dose and change in PANSS total score or change in any of the PANSS subscores.
Discussion
This is to our knowledge the first longitudinal study to examine whether patients with different treatment response regarding NS have a different pattern of reward alteration in striatum before and after antipsychotic medication. We found that patients improving in NS score after 6 weeks of monotherapy with amisulpride had a more normal anticipation activity in striatum at baseline, despite a higher level of NS. Furthermore, these patients had a decrease in reward anticipation activity following treatment despite the improvement in NS score. On the contrary, patients characterized as nonimprovers had a reduced anticipation activity in striatum at baseline regardless of a lower level of NS. These patients improved in reward anticipation activity even though they did not improve in the NS score.
These results were unexpected as several studies have described a relation between NS and decreased contrast signal in striatum during reward anticipation. 9, 15, 18, 47 Accordingly, we would expect any baseline group difference to be in the opposite direction, thus the patients with a higher level of NS should have the most attenuated reward response.
One important consideration may explain this observation: The NS that do improve over time may be the NS that are secondary to other symptoms as anxiety, depression, or psychosis, whereas the NS present at baseline in the nonimproving patients to a higher degree may represent primary NS, which do not change with treatment. The PANSS scale does not make it possible to separate primary NS from secondary NS, however, patients improving in NS over time had a higher baseline level and a more pronounced improvement of general symptoms, which may support this consideration. Nevertheless, the baseline level and the improvement of positive symptoms was the same in both groups, and may argue against this. Difficulties in separating primary and secondary NS symptoms make it impossible to evaluate whether this is the case in the current study. The study by Levine and Leucht 30 presenting the different response trajectories do not contribute with further observations that could either support or disprove this consideration.
Another important type of secondary NS is the sedation, apathy, and anhedonia that some patients experience as a side effect to antipsychotic medication. In the current cohort, we would expect this kind of NS to occur in the non-improving group, who on average did have a small increase in the NS score over time. If these symptoms were related to the medication effect on reward alterations, we would expect this group to have a more aberrant reward signal after receiving medication. This was, however, not the case; on the contrary, we observed an increase of the reward anticipation signal in this group.
To understand our unexpected results, we need to pay further attention to the different development of the reward activity over time in the three groups. In healthy controls, we observed a decrease in activity during reward anticipation. This is consistent with previous findings in longitudinal studies 24, 25 and could be a habituation effect because of practicing the paradigm. In the NS improvers, we likewise observed a reduction in the contrast signal following treatment, which could be a similar habituation effect. In the NS nonimprovers, the contrast signal in striatum increased the second time they were scanned. We have previously interpreted this increased contrast signal as a normalization of the dopaminergic signaling caused by a balanced dopamine D2 blockade which improve the positive symptoms. 25 This may still be the case, but it does not address why the contrast signal change differently in the 2 groups of patients, as the groups do not differ in the aspect of positive symptoms. Furthermore, there are no differences in the mean dose of amisulpride, which makes it unlikely that this group difference depends on medication dose.
In order to explain the different development of the contrast signal over time it may be appropriate to take a look at the mechanism of reward/reinforcement learning. As described by Schultz et al, 48 the dopamine cells projecting to ventral striatum initially fires in relation to a reward. However, when a cue is repetitively presented prior to the reward, the dopamine signaling will within a short while shift to the time of the cue and thus indicate the salience of the cue. This reinforcement learning normally takes place within minutes, and as the MID task is usually practiced for 10 minutes outside the scanner, the shifting of the signal is expected to have occurred before the beginning of the scanning. In schizophrenia patients, reinforcement learning is generally impaired. 21, 22, 49 This impairment has been proposed as a mechanism underlying the attenuated striatal signaling 50 and further, it has been linked to the severity of NS.
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Impaired/delayed reinforcement learning could be a possible explanation of the initial reduction and the later increase in the signal in striatum. In that case, our results suggest that this impairment is most pronounced in the patients with persistent/ nonimproving NS. The explorative findings of differences in the frontal areas support the importance of addressing the impact of reinforcement learning on NS in future studies. In the current study, NS was only measured by the PANSS rating scale. Although this scale has been used in several other studies, 9, 15 it is, according to the more recent guidelines, not a well-designed scale for measuring NS. 51, 52 As stated by these guidelines, NS can be divided into several constructs and subdomains, which may be more relevant to use when searching for neural correlates of NS than an overall measure of NS. Recent studies have indeed focused on these more specific subdomains of NS. For instance, Kirschner et al 53 showed that apathy but not diminished expression was related to reduced ventral striatal reward activity. Likewise, Mucci et al 54 found an association between aberrant caudate reward activity and avolition but no association with anhedonia. This may point to a specific relation between apathy/avolition and ventral striatal hypoactivation, but unfortunately, the PANSS scale is not well suited for examining such NS subdomains.
Conclusion
In this longitudinal study on initially antipsychotic-naive schizophrenia patients, we did not find a direct association between the overall measure of NS and altered ventral striatal activity during anticipation of salient events. We did, however, find that patients not improving in NS over time had the most aberrant reward related activity in striatum, which normalized over time. Whether this is associated with alteration in working memory and reward learning or with pronounced symptoms within specific domains of NS may be addressed in future studies.
